These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 33936104)

  • 1. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.
    Sinagra JL; Vedovelli C; Binazzi R; Salemme A; Moro F; Mazzanti C; Didona B; Di Zenzo G
    Front Immunol; 2021; 12():665522. PubMed ID: 33936104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
    Róbert L; Kovács A; Sárdy M; Fábián M
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemphigus: Current and Future Therapeutic Strategies.
    Didona D; Maglie R; Eming R; Hertl M
    Front Immunol; 2019; 10():1418. PubMed ID: 31293582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.
    Hébert V; Petit M; Maho-Vaillant M; Golinski ML; Riou G; Derambure C; Boyer O; Joly P; Calbo S
    Front Immunol; 2019; 10():1794. PubMed ID: 31440235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
    Maho-Vaillant M; Perals C; Golinski ML; Hébert V; Caillot F; Mignard C; Riou G; Petit M; Viguier M; Hertl M; Boyer O; Calbo S; Fazilleau N; Joly P
    J Invest Dermatol; 2021 Sep; 141(9):2132-2140.e1. PubMed ID: 33766510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemphigus.
    Schmidt E; Kasperkiewicz M; Joly P
    Lancet; 2019 Sep; 394(10201):882-894. PubMed ID: 31498102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
    Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
    Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-CoV-2 in pemphigus cases.
    Pawar M; Singh M
    Clin Dermatol; 2020; 38(6):750-756. PubMed ID: 33341209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in pemphigus.
    Hebert V; Joly P
    Immunotherapy; 2018 Jan; 10(1):27-37. PubMed ID: 29064314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen.
    Hébert V; Maho-Vaillant M; Golinski ML; Petit M; Riou G; Boyer O; Musette P; Calbo S; Joly P
    Front Immunol; 2021; 12():666022. PubMed ID: 34054835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients.
    Song A; Jang J; Lee A; Min SY; Lee SG; Kim SC; Shin J; Kim JH
    Front Immunol; 2022; 13():932909. PubMed ID: 35983042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
    Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
    Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
    Colliou N; Picard D; Caillot F; Calbo S; Le Corre S; Lim A; Lemercier B; Le Mauff B; Maho-Vaillant M; Jacquot S; Bedane C; Bernard P; Caux F; Prost C; Delaporte E; Doutre MS; Dreno B; Franck N; Ingen-Housz-Oro S; Chosidow O; Pauwels C; Picard C; Roujeau JC; Sigal M; Tancrede-Bohin E; Templier I; Eming R; Hertl M; D'Incan M; Joly P; Musette P
    Sci Transl Med; 2013 Mar; 5(175):175ra30. PubMed ID: 23467561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.
    Hammers CM; Chen J; Lin C; Kacir S; Siegel DL; Payne AS; Stanley JR
    J Invest Dermatol; 2015 Mar; 135(3):742-749. PubMed ID: 25142730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.
    Feldman RJ; Ahmed AR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):529-41. PubMed ID: 21790294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab exerts a dual effect in pemphigus vulgaris.
    Eming R; Nagel A; Wolff-Franke S; Podstawa E; Debus D; Hertl M
    J Invest Dermatol; 2008 Dec; 128(12):2850-8. PubMed ID: 18563178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.
    Nagel A; Podstawa E; Eickmann M; Müller HH; Hertl M; Eming R
    J Invest Dermatol; 2009 Sep; 129(9):2202-10. PubMed ID: 19282839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study.
    Kanwar AJ; Vinay K; Sawatkar GU; Dogra S; Minz RW; Shear NH; Koga H; Ishii N; Hashimoto T
    Br J Dermatol; 2014 Jun; 170(6):1341-9. PubMed ID: 24640990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.